CompletedNot Applicable

Evaluatıon of TREM-1, MMP-8 and TIMP-1 Levels in Perı-Implant Crevicular Fluıd of Perı-Implanted Indıvıduals

Turkey (Türkiye)54 participantsStarted 2023-06-01

Plain-language summary

The aim of this study was to evaluate the relationship between Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1), Matrix Metalloproteinases-8 (MMP-8) and Tissue Inhibitors of Metalloproteinases-1 (TIMP-1) levels in peri-implant crevicular fluid (PICF) in peri-implantitis patients.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Systemically healthy * Pregnancy or lactation Exclusion Criteria: * osteoporosis * rheumatoid arthritis * autoimmune disease * diabetes

What they're measuring

TREM-1, MMP-8 and TIMP-1 levels in PICF samples

Timeframe: 1 month

Trial details

NCT IDNCT07379892

SponsorAydin Adnan Menderes University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-12-15

View on ClinicalTrials.gov More Periimplantitis trials